GCM
STLN

Graham Capital Management’s Starling Oncology STLN Stock Holding History

Graham Capital Management’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-33,792
Closed -$104K – 1510
2026
Q1 		$104K Buy
+33,792
New +$104K ﹤0.01% 1036
2025
Q4 		– Sell
-72,408
Closed -$253K – 1582
2025
Q3 		$253K Sell
72,408
-13,798
-16% -$47.3K ﹤0.01% 936
2025
Q2 		$177K Buy
+86,206
New +$216K ﹤0.01% 1144

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Graham Capital Management's STLN Position: Q2 2026 in Review

Graham Capital Management sold out of Starling Oncology (STLN) in Q2 2026, closing a stake of 33,792 shares — an estimated $104K sold.

Graham Capital Management first reported a position in STLN in Q2 2025 and held it in 3 quarters. The position peaked at $253K in Q3 2025. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • Graham Capital Management reported no remaining Starling Oncology position as of Q2 2026 after selling out during the quarter.
  • Graham Capital Management sold 33,792 Starling Oncology shares in Q2 2026, an estimated $104K.
  • Graham Capital Management first reported a position in Starling Oncology in Q2 2025 and held it in 3 quarters.
  • Graham Capital Management's Starling Oncology position peaked at $253K in Q3 2025.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.